Objective. There is growing evidence that hypertensive pregnancy complications and other adverse pregnancy outcomes are associated with the presence of inherited or acquired thrombophilias. As hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome is one of the most severe forms of pre-eclampsia we aimed to assess the prevalence of the factor V Leiden, the prothrombin 20210G >A mutation and the methylenetetrahydrofolate reductase (MTHFR) 677C >T polymorphism in women with HELLP syndrome and in their fetuses from the same index pregnancy. Design. The study was performed retrospectively in a case-control design. Sample. Seventy-one mother-child pairs with HELLP syndrome and 79 control mother-child pairs with uncomplicated pregnancies were included in the study. Methods. Genotyping of the three thrombophilic mutations was performed using the LightCycler technology. The chi-squared test was used for statistical analysis. Main outcome measures were maternal and fetal genotypes and their correlation with clinical parameters. Results. Maternal heterozygosity for factor V Leiden was significantly more prevalent in the HELLP group than in controls (OR 4.45,. No significant association was observed for maternal prothrombin mutation or MTHFR polymorphism (p=0.894, p=0.189, respectively). The fetal genotype was not associated with HELLP syndrome for any of the three mutations investigated. Analysis of gene-gene interactions and genotype-phenotype correlation with respect to clinical parameters and perinatal outcome revealed no further differences. Conclusions. Our study confirms that women heterozygous for factor V Leiden have an increased risk of developing HELLP syndrome, while the most frequent mutations of the prothrombin and MTHFR gene do not play a major role in the pathogenesis of HELLP syndrome. 
Introduction
HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome is a life-threatening form of pre-eclampsia, complicating about 0.17 -0.8% of all live births (1) . Diagnosis of HELLP is based on the evidence of intravascular hemolysis, impaired liver function and thrombocytopenia. Approximately 15% of women with pre-eclampsia/eclampsia show the complete spectrum of HELLP syndrome and thus have an increased risk for significant perinatal morbidity and mortality, both maternal and fetal (2) .
There is growing evidence that hypertensive pregnancy complications and other adverse pregnancy outcomes are associated with the presence of inherited or acquired thrombophilias (3;4) . However, the results of single studies remain controversial. Most of the inherited thrombophilias are found in the protein C system and affect the physiological balance between pro-and anticoagulant factors (5) . Inherited resistance to activated protein C (APC) is known as risk factor for thrombosis. A single point mutation in the gene for factor V (G to A transition at nucleotide position 1691, factor V Leiden mutation), which predicts replacement of Arg(R)506 in the APC-cleavage site with a Gln(Q) and results in an impaired degradation of factor V, accounts for more than 90% of the cases of APC-resistance (6) . The prevalence of factor V Leiden mutation in the normal population ranges from 3 to 7% in Europe and the USA (7).
The prothrombin gene mutation (20210G>A) is a second common genetic risk factor for thrombosis, leading to an increased plasma concentration of prothrombin with a subsequently higher rate of fibrin formation (8) . In Europe the carrier frequency of the prothrombin mutation is reported to be 1-4% with a nearly twofold higher prevalence in Southern than in Northern Europe (9) .
Homozygosity for the polymorphism 677C>T in the methylenetetrahydrofolate reductase (MTHFR) gene is associated with hyperhomocysteinemia and may thus increase the risk for vascular disorders (10) . The MTHFR 677C>T polymorphism can be found in homozygous state in about 14% of the general Caucasian population with higher carrier rates in Southern compared to Northern Europe (11) .
Over the last decade more than 70 studies including several meta-analyses have investigated the prevalence of thrombophilic gene mutations in pre-eclampsia, yielding contradictory results [for review see (4;12) ]. Only 14 studies have addressed the association between these mutations and the development of HELLP syndrome, also reporting conflicting data (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) .
Most of these studies have included a small number of HELLP patients and have not assessed the fetal genotype. Furthermore, data from HELLP patients are often included in the results for pre-eclampsia patients.
In this study we aimed to assess the prevalence of the most common inherited thrombophilias factor V Leiden, prothrombin 20210G>A and MTHFR 677C>T in a well-defined cohort of Caucasian women with a history of HELLP syndrome compared to healthy female controls.
As vascular features of the placenta are thought to be involved in the pathogenesis of preeclampsia, and as the placenta is of fetal origin (27;28) , fetuses from the index pregnancies were also genotyped for the three common thrombophilic mutations in order to determine whether a paternal contribution is of central importance.
Materials and Methods

Study cohort
71 women with HELLP syndrome and their children from the index pregnancy were included in our study. Patients were recruited at the Department of Obstetrics and Gynecology, Aachen University Hospital, and nationwide by the German pre-eclampsia society. 79 healthy motherchild-pairs with uncomplicated pregnancies who delivered at Aachen Univeristy Hospital or obstetric departments in the surrounding area were enrolled as controls. All subjects were of white Caucasian origin. The diagnosis of HELLP syndrome was based on the presence of hemolytic anemia (serum haptoglobin levels < 0.3 g/L or serum lactate dehydrogenase (LDH) > 300 IU/L), elevated liver enzymes (elevation of serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) over norm), and evidence of thrombocytopenia, defined as a platelet count of < 100.000/µl. The study was approved by the Institutional Ethics Committee and informed consent was obtained from all subjects.
DNA studies
Genomic DNA was isolated from blood leukocytes as described by Miller et al. (29) . Analysis of the defined point mutations of factor V, prothrombin and MTHFR was performed using the 
Statistical analysis
Results for the two groups were compared by using the χ 2 -test. p-values < 0.05 were regarded as statistically significant. Statistical analyses were performed with SPSS for Windows®.
Results
Clinical characteristics of the study groups are shown in Furthermore, analyis of gene-gene interactions in the mother, in the fetus and between mother and fetus was performed. In the HELLP group, neither mothers nor children were compound heterozygous for factor V Leiden or the prothrombin gene mutation whereas among the controls, one child and one mother were compound heterozygous. Only one child in the HELLP group carried the MTHFR-677-TT genotype and was heterozygous for the prothrombin gene mutation. The combination of heterozygous factor V Leiden and homozygosity for MTHFR -677-T was not found at all in our study population. Regarding the gene-gene interactions between mother and fetus, the frequency of mothers who had inherited the mutant allele to their offspring was the same in patients and controls for the tree mutations investigated.
Discussion
To our knowledge this is the largest study published so far on the relation between HELLP syndrome and the thrombophilic gene mutations factor V Leiden, prothrombin 20210G>A
MTHFR in mothers and fetuses. The post hoc statistical power calculation revealed that given 17% heterozygosity in the HELLP group and 4% in the control population and accepting an alpha error level of 10%, the statistical power would be as high as 91%.
Previous association studies on thrombophilic genotypes and HELLP syndrome are summarized in Table 4 Fetal genes related to vascular conditions are also supposed to influence the risk of preeclampsia and HELLP because the placenta is of fetal origin and vascular features of the placenta are thought to be involved in the pathogenesis of these disorders (27;28) . Therefore we assessed the fetal genotype for factor V Leiden, prothrombin 20210G>A and MTHFR 677C>T. No influence on maternal risk of HELLP syndrome was observed.
Several studies have addressed the role of fetal inherited thrombophilias in pre-eclampsia, only three of them have included a small number of HELLP pregnancies (Table 5 ) (19, 23, 28, (33) (34) (35) (36) (37) (38) . On the whole, there was no evidence for a strong association. Nevertheless, Dizon-Townson et al. (35) found a trend towards an increase of maternal pre-eclampsia among fetal factor V Leiden carriers (p=0.06) which became significant when the cases were separated according to ethnicity. In African-American and Hispanic mothers of fetal factor V Leiden carriers, pre-eclampsia revealed to be significantly more frequent than in whites (p=0.04). Furthermore, Anteby et al. (33) showed that fetal factor V Leiden and prothrombin mutations may lead to a more severe course of pre-eclampsia, intrauterine growth-restriction and placental abruption: Fetuses with factor V Leiden or prothrombin mutation were born earlier (p=0.04) and weighed less (p=0.02) than fetuses without these thrombophilic mutations. Thus a certain fetal impact on maternal pre-eclampsia and other severe obstetric complications may not be completely ruled out. Our results clearly show that there is no paternal effect in addition to maternal inheritance of factor V Leiden mutation which should be found with an increased frequency in the fetuses since the mutation is more prevalent in mothers with HELLP syndrome.
In summary, our data confirm that Caucasian women carrying a heterozygous factor V Leiden mutation have an increased risk of developing HELLP syndrome (OR 4.45). In contrast, no significant association was found for prothrombin 20210G>A mutation and MTHFR 677C>T polymorphism. No further differences were detected when thrombophilic genotypes were related to the clinical features of HELLP syndrome and perinatal outcome. Moreover, there was no evidence for a fetal genetic influence on the mother´s risk of developing HELLP syndrome. We further may conclude from our study that gene-gene interactions do not have a major impact on the role of thrombophilic mutations in the etiolgy of HELLP syndrome. 
